The FDA recently approved Medtronic’s technologically advanced deep brain stimulation (DBS) system that has been designed to target motor symptoms in Parkinson’s disease, dystonia or essential tremor in a precise manner. The SenSight Directional Lead System for DBS therapy integrates the sensing capability that allows real-time monitoring of brain signals and a directional lead that enables localization of abnormal signals and effective steering of electric current. This is the first-ever DBS system where both the technologies are being used in unison and it may lead to better outcomes with fewer adverse effects as it is capable of adjusting therapeutic stimulation in response to continuously recorded brain signals.
